Late‐Onset Neutropenia in Long‐Term Clozapine Use and Its Management Utilizing Prophylactic G‐CSF
E O'Neill, D Carolan, S Kennedy… - Case Reports in …, 2021 - Wiley Online Library
This case outlines recurrent neutropenia after fourteen years of successful clozapine use.
The patient has a diagnosis of treatment‐resistant schizophrenia which has been …
The patient has a diagnosis of treatment‐resistant schizophrenia which has been …
Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing Prophylactic G-CSF.
E O'Neill, D Carolan, S Kennedy… - Case Reports in …, 2021 - europepmc.org
This case outlines recurrent neutropenia after fourteen years of successful clozapine use.
The patient has a diagnosis of treatment-resistant schizophrenia which has been …
The patient has a diagnosis of treatment-resistant schizophrenia which has been …
[引用][C] Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing Prophylactic G-CSF
E O'Neill, D Carolan, S Kennedy… - Case Reports in …, 2021 - jglobal.jst.go.jp
Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing
Prophylactic G-CSF | Article Information | J-GLOBAL Art J-GLOBAL ID:202102284757414452 …
Prophylactic G-CSF | Article Information | J-GLOBAL Art J-GLOBAL ID:202102284757414452 …
Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing Prophylactic G-CSF.
E O'Neill, D Carolan, S Kennedy… - Case Reports in …, 2021 - search.ebscohost.com
This case outlines recurrent neutropenia after fourteen years of successful clozapine use.
The patient has a diagnosis of treatment-resistant schizophrenia which has been …
The patient has a diagnosis of treatment-resistant schizophrenia which has been …
[PDF][PDF] Case Report Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing Prophylactic G-CSF
E O'Neill, D Carolan, S Kennedy, S Barry - 2021 - pdfs.semanticscholar.org
1. Background Treatment-resistant schizophrenia is an enduring and challenging illness
which affects twenty to thirty-three percent of the treatment-resistant population or one third …
which affects twenty to thirty-three percent of the treatment-resistant population or one third …
Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing Prophylactic G-CSF
E O'Neill, D Carolan, S Kennedy… - Case Reports in …, 2021 - search.proquest.com
This case outlines recurrent neutropenia after fourteen years of successful clozapine use.
The patient has a diagnosis of treatment-resistant schizophrenia which has been …
The patient has a diagnosis of treatment-resistant schizophrenia which has been …
[PDF][PDF] Case Report Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing Prophylactic G-CSF
E O'Neill, D Carolan, S Kennedy, S Barry - 2021 - academia.edu
1. Background Treatment-resistant schizophrenia is an enduring and challenging illness
which affects twenty to thirty-three percent of the treatment-resistant population or one third …
which affects twenty to thirty-three percent of the treatment-resistant population or one third …
[HTML][HTML] Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing Prophylactic G-CSF
E O'Neill, D Carolan, S Kennedy… - Case Reports in …, 2021 - ncbi.nlm.nih.gov
This case outlines recurrent neutropenia after fourteen years of successful clozapine use.
The patient has a diagnosis of treatment-resistant schizophrenia which has been …
The patient has a diagnosis of treatment-resistant schizophrenia which has been …
[PDF][PDF] Case Report Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing Prophylactic G-CSF
E O'Neill, D Carolan, S Kennedy, S Barry - 2021 - scienceopen.com
1. Background Treatment-resistant schizophrenia is an enduring and challenging illness
which affects twenty to thirty-three percent of the treatment-resistant population or one third …
which affects twenty to thirty-three percent of the treatment-resistant population or one third …
[PDF][PDF] Case Report Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing Prophylactic G-CSF
E O'Neill, D Carolan, S Kennedy, S Barry - 2021 - researchgate.net
1. Background Treatment-resistant schizophrenia is an enduring and challenging illness
which affects twenty to thirty-three percent of the treatment-resistant population or one third …
which affects twenty to thirty-three percent of the treatment-resistant population or one third …